Citations

Showing 10 of 108119 citations.

Speech Perception Performance Growth and Benchmark Score Achievement After Cochlear Implantation for Single-Sided Deafness
Nassiri, Ashley M. , Wallerius, Katherine P. , Lohse, Christine M. , Marinelli, John P. , Saoji, Aniket A. , Driscoll, Colin L. W., Neff, Brian A., Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | December 10, 2021 | Volume: 43 | Issue: 1 | Pages: e64-e71

10.1097/mao.0000000000003407 | PMID 34889843 Get It

Objectives: Compare speech perception performance growth and benchmark score achievement among adult cochlear implant (CI) recipients with single-sided deafness (SSD) versus bilateral moderate to profound hearing loss. Study Design: Retrospective matched cohort analysis. Setting: Tertiary referral center. Patients: Adults with SSD or bilateral moderate to profound hearing sensorineural hearing loss who underwent cochlear implantation from 2014 to 2019. Interventions: Cochlear implantation. Main outcome measures: Time-to-benchmark speech perception score (CNC, AzBio in quiet) and speech performance within first postoperative year. Results: Thirty-three SSD patients were matched to 66 bilateral hearing loss patients (referent cohort) for duration of deafness and preoperative ipsilateral CNC scores. Although SSD patients were more likely to achieve benchmark CNC scores more quickly compared with matched referents, this difference did not reach statistical significance (HR 1.72; 95% CI 0.78–3.82; p = 0.18). AzBio scores showed similar trends (HR 1.40; 95% CI 0.66–2.98; p = 0.38). At last follow-up, the SSD cohort had lower CNC (median 54% vs. 62%; p = 0.019) and AzBio scores (median 72% vs. 84%; p = 0.029) compared to the referent cohort. Conclusions: No significant difference in speech perception performance growth (i.e., time-to-benchmark speech perception score) was identified between SSD and bilateral hearing loss CI recipients, although patients with bilateral hearing loss achieved higher scores in the implanted ear within the first year of follow-up.
Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD)
Tilburt, Jon C. , Zahrieh, David , Pacyna, Joel E. , Petereit, Daniel G. , Kaur, Judith S. , Rapkin, Bruce D. , Grubb, Robert L., Chang, George J. , Babaian, Kara N., Sloan, Jeff A. , Basch, Ethan , Peil, Elizabeth S., Dueck, Amylou C. , Novotny, Paul J. , Buckner, Jan C. , Joyce, Daniel , Frosch, Dominick L. , Kim, Simon P. , Basch, Ethan , Joyce, Daniel D., Volk, Robert J , Dueck, A. C. , Joyce, Daniel D , Morris, Michael J. , Kovac, Evan Z. , Paskett, Electra D. , Montori, Víctor M.

Mayo Clinic

Cancer | December 10, 2021 | Volume: 128 | Issue: 6 | Pages: 1242-1251

10.1002/cncr.34062 | PMID 34890060 Get It

BackgroundDecision aids (DAs) can improve knowledge for prostate cancer treatment. However, the relative effects of DAs delivered within the clinical encounter and in more diverse patient populations are unknown. A multicenter cluster randomized controlled trial with a 2×2 factorial design was performed to test the effectiveness of within‐visit and previsit DAs for localized prostate cancer, and minority men were oversampled.MethodsThe interventions were delivered in urology practices affiliated with the NCI Community Oncology Research Program Alliance Research Base. The primary outcome was prostate cancer knowledge (percent correct on a 12‐item measure) assessed immediately after a urology consultation.ResultsFour sites administered the previsit DA (39 patients), 4 sites administered the within‐visit DA (44 patients), 3 sites administered both previsit and within‐visit DAs (25 patients), and 4 sites provided usual care (50 patients). The median percent correct in prostate cancer knowledge, based on the postvisit knowledge assessment after the intervention delivery, was as follows: 75% for the pre+within‐visit DA study arm, 67% for the previsit DA only arm, 58% for the within‐visit DA only arm, and 58% for the usual‐care arm. Neither the previsit DA nor the within‐visit DA had a significant impact on patient knowledge of prostate cancer treatments at the prespecified 2.5% significance level (P = .132 and P = .977, respectively).ConclusionsDAs for localized prostate cancer treatment provided at 2 different points in the care continuum in a trial that oversampled minority men did not confer measurable gains in prostate cancer knowledge.
Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma
Hosseini, Mojgan , Allende, Daniela , Esposito, Iréne , Shi, Jiaqi , Dhall, Deepti, Graham, Rondell P. , Baştürk, Olca , Hruban, Ralph H. , Klimstra, David S. , Adsay, Volkan , Society, for the Pancreatobiliary Pathology, Graham, Rondell P , Adsay, N Volkan , Wang, Huamin , Chetty, Runjan , Matsuda, Yoko , Deshpande, Vikram , Jang, Kee‐Taek , Kim, Grace , Luchini, Claudio , Reid, Michelle D. , Krasinskas, Alyssa M. , Society, for the Pancreatobiliary Pathology

Mayo Clinic

American Journal of Surgical Pathology | December 10, 2021 | Volume: 46 | Issue: 6 | Pages: 754-764

10.1097/pas.0000000000001853 | PMID 34889852 Get It

Currently, there are no internationally accepted consensus guidelines for pathologic evaluation of posttherapy pancreatectomy specimens. The Neoadjuvant Therapy Working Group of Pancreatobiliary Pathology Society was formed in 2018 to review grossing protocols, literature, and major issues and to develop recommendations for pathologic evaluation of posttherapy pancreatectomy specimens. The working group generated the following recommendations: (1) Systematic and standardized grossing and sampling protocols should be adopted for pancreatectomy specimens for treated pancreatic ductal adenocarcinoma (PDAC). (2) Consecutive mapping sections along the largest gross tumor dimension are recommended to validate tumor size by histology as required by the College of American Pathologists (CAP) cancer protocol. (3) Tumor size of treated PDACs should be measured microscopically as the largest dimension of tumor outer limits that is bound by viable tumor cells, including intervening stroma. (4) The MD Anderson grading system for tumor response has a better correlation with prognosis and better interobserver concordance among pathologists than does the CAP system. (5) A case should not be classified as a complete response unless the entire pancreas, peripancreatic tissues, ampulla of Vater, common bile duct, and duodenum adjacent to the pancreas are submitted for microscopic examination. (6) Future studies on tumor response of lymph node metastases, molecular and/or immunohistochemical markers, as well as application of artificial intelligence in grading tumor response of treated PDAC are needed. In summary, systematic, standardized pathologic evaluation, accurate tumor size measurement, and reproducible tumor response grading to neoadjuvant therapy are needed for optimal patient care. The criteria and discussions provided here may provide guidance towards these goals.
A NET gain in our understanding of acute liver failure
Hilscher, Moira , Shah, Vijay H.

Mayo Clinic

Hepatology | December 10, 2021 | Volume: 75 | Issue: 3 | Pages: 511-513

10.1002/hep.32278 | PMID 34890053 Get It

A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis
Cudkowicz, Merit , Lindborg, Stacy , Goyal, Namita , Miller, Robert G. , Burford, Matthew, Nicholson, Katharine, Mozaffar, Tahseen , Katz, Jonathan, Jenkins, Liberty, Baloh, Robert H. , Lewis, Richard A. , Staff, N., Owegi, Margaret, Berry, Donald A. , Gothelf, Yaël, Levy, Yossef S., Aricha, Revital , Kern, R. , Windebank, Anthony J. , Brown, Robert H. , Staff, Nathan P. , Cudkowicz, Merit E , Lindborg, Stacy R , Mozaffar, Tahseen , Lewis, Richard A , Brown, Robert H , Staff, Nathan P , Berry, James D.

Mayo Clinic

Muscle & Nerve | December 10, 2021 | Volume: 65 | Issue: 3 | Pages: 291-302

10.1002/mus.27472 | PMID 34890069 Get It

Abstract Introduction/Aims Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative illness with great unmet patient need. We aimed to evaluate whether mesenchymal stem cells induced to secrete high levels of neurotrophic factors (MSC‐NTF), a novel autologous cell‐therapy capable of targeting multiple pathways, could safely slow ALS disease progression. Methods This randomized, double‐blind, placebo‐controlled study enrolled ALS participants meeting revised El Escorial criteria, revised ALS Functional Rating Scale (ALSFRS‐R) ≥25 (screening) and ≥3 ALSFRS‐R points decline prior to randomization. Participants received three treatments of MSC‐NTF or placebo intrathecally. The primary endpoint evaluated efficacy of MSC‐NTF through a responder analysis and safety. A change in disease progression post‐treatment of ≥1.25 points/mo defines a clinical response. A pre‐specified analysis leveraged baseline ALSFRS‐R of 35 as a subgroup threshold. Results Overall, MSC‐NTF treatment was well tolerated; there were no safety concerns. Thirty‐three percent of MSC‐NTF and 28% of placebo participants met clinical response criteria at 28 wk (odds ratio [OR] = 1.33, P = .45); thus, the primary endpoint was not met. A pre‐specified analysis of participants with baseline ALSFRS‐R ≥ 35 (n = 58) showed a clinical response rate at 28 wk of 35% MSC‐NTF and 16% placebo (OR = 2.6, P = .29). Significant improvements in cerebrospinal biomarkers of neuroinflammation, neurodegeneration, and neurotrophic factor support were observed with MSC‐NTF, with placebo unchanged. Discussion The study did not reach statistical significance on the primary endpoint. However, a pre‐specified subgroup suggests that MSC‐NTF participants with less severe disease may have retained more function compared to placebo. Given the unmet patient need, the results of this trial warrant further investigation.
RADIOISOTOPE RENOGRAPHY IN CHILDREN
Wenzl, James E., Tauxe, W. Newlon, Burke, Edmund C., Hunt, James C., Stickler, Gunnar B.

Mayo Clinic

Pediatrics | December 10, 2021 | Volume: 36 | Issue: 2 | Pages: 200-206

10.1542/peds.36.2.200 Get It

Radioisotope renograms with orthoiodohippurate-I131 were obtained for 41 children who had known renal or renovascular disorders. (Two patients had hypertension but no evidence of renal disease.) Values determined for various components of the renogram curves were considered abnormal when they exceeded two standard deviations from the mean values for normal children of similar body surface area or when time B (from injection to the point of maximal radioactivity) exceeded 6.5 minutes or differed from the contralateral kidney by more than 1 minute. The renogram was clearly abnormal in all 17 patients who had unilateral or predominantly unilateral renal disorders. Abnormalities associated with bilateral renal disorders varied with the disease and its severity. The clinical severity of impairment of renal function could be estimated from the renogram. The isotope renogram proved to be a simple, reproducible technique for determination of function of the separate kidneys.
RADIOISOTOPE RENOGRAPHY IN CHILDREN. I. THE RENOGRAM IN CHILDREN WITHOUT RENAL DISEASE
Wenzl, James E., Tauxe, W. Newlon, Burke, Edmund C., Hunt, James C., Stickler, Gunnar B.

Mayo Clinic

Pediatrics | December 10, 2021 | Volume: 36 | Issue: 1 | Pages: 120-127

10.1542/peds.36.1.120 Get It

Isotope renograms (ortho-iodohippurate-I were obtained from 30 children who had no evidence of renal disease. Determinations were made by a standardized technique with the subjects in a state of relative dehydration; in 15 children the renogram was repeated under conditions of hydration (14 children) or further dehydration (1 child). Values for the point of initial peak (point A), point of maximal radioactivity (point B), and the differences between these points (B-A) were calculated. These values were plotted arithmetically against surface area to obtain regression lines and estimates of the variability of the observations about the line. The time from appearance of radioactivity to peak radioactivity was calculated and found to fall into a relatively narrow range. Similar attempts to correlate mathematically the height of timed segments of the decreasing slope of the renogram with surface area were successful in children with a body surface area of 1.15 m2 or greater. The state of hydration appeared to influence the excretory slope of the renogram; this effect was most pronounced in children whose total body surface area was less than 1.15 m2.
HEAD CIRCUMFERENCE, MENTAL RETARDATION, AND GROWTH FAILURE
O’Connell, Edward J., Stickler, Gunnar B., Feldt, Robert

Mayo Clinic

Pediatrics | December 10, 2021 | Volume: 36 | Issue: 1 | Pages: 62-66

10.1542/peds.36.1.62 Get It

The purpose of this study was to re-affirm our clinical impression that non-institutionalized children whose head circumference was below minus 2 standard deviations were mentally subnormal and frequently had growth failure. A group of 134 children with a head circumference below minus 2 standard deviations from the mean were studied, and all but one were mentally subnormal. The most severe mental retardation was noted in the group of children with a head circumference of minus 4 standard deviations or below. We found, as have others, that children with mental retardation have height and weights below the expected norm and that children with a head circumference below minus 2 standard deviations have even lower mean heights and weights. The head circumference of 31 children with growth failure and normal intelligence was normal for age and sex, therefore disproving the concept that the abnormally small child has a proportionally small head. In the child with growth failure, should the head be proportionally small (below minus 2 standard deviations), mental subnormality should be suspected. We feel that the head circumference measurement has taken on new clinical significance in that our data support its use in suspecting the association of mental subnormality in children with growth failure and a head circumference of below minus 2 standard deviations from the mean for age and sex.
Letters to the Editor
O’Connell, Edward J., Stickler, Gunnar B., Feldt, Robert

Mayo Clinic

Pediatrics | December 10, 2021 | Volume: 37 | Issue: 2 | Pages: 385-386

10.1542/peds.37.2.385 Get It

Replying to Dr. I. Krieger's letter to the editor poses difficulties. In using this communication for submission of her own data for publication, she has not felt the need to provide the careful documentation that would allow critical analysis. For example, her statement that "small stature, small head size, and mental subnormality are frequently associated" is true on the basis of our experience but is not supported by her recorded data. No psychometric test results are noted in the text or in the illustrations accompayning her letter.
CENTRAL NERVOUS SYSTEM COMPLICATIONS FOLLOWING BLALOCK-TAUSSIG OPERATION
Clarkson, P. M., Gómez, Manuel R., Wallace, Robert B. , Weidman, William H.

Mayo Clinic

Pediatrics | December 10, 2021 | Volume: 39 | Issue: 1 | Pages: 18-23

10.1542/peds.39.1.18 Get It

Two cases of severe neurologic symptoms after a Blalock-Taussig anastomosis are presented in detail. The histories of 116 patients with cyanotic congenital heart disease who had such an anastomotic operation at the Mayo Clinic were reviewed. There was a low incidence (less than 1%) of postoperative neurologic complications in patients without evidence of focal dysfunction of the central nervous system prior to operation. The review suggested an increased incidence of complications in those patients with a cerebrovascular abnormality before surgery. It is likely that these complications are related to alterations in the vertebrobasilar arterial system associated with this procedure.